Ownership and insider activity for PureTech Health plc (PRTC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others.
Price
| Price | $17.38 |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2022-01-13 | PureTech Health plc | |||
| 2022-01-13 | PureTech Health plc | 77,760 | $315K | |
| 2022-01-13 | PureTech Health plc | 216,208 | $4K | |
| 2022-01-13 | PureTech Health plc | 4,526,622 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63.0M | $72.6M | $117.1M | $132.4M | $403.9M | $465.7M | $149.9M | $191.1M | $280.6M | $254.1M |
| Short-term Investments | $219.4M | $117.0M | $133.8M | $30.1M | 0 | 0 | $200.2M | $136.1M | $86.7M | $24.8M |
| Receivables | $125000 | $1.8M | $1.3M | $2.3M | $2.9M | $3.6M | $22.4M | $2.4M | $12.9M | $8.1M |
| Inventory | -$1.9M | -$2.7M | -$1.3M | 0 | 0 | $28.0M | 0 | 0 | 0 | 0 |
| Total Current Assets | $288.2M | $198.1M | $259.8M | $168.8M | $414.3M | $501.8M | $386.2M | $347.2M | $386.3M | $305.0M |
| Property, Plant & Equipment | $6.9M | $6.9M | $8.3M | $43.8M | $42.9M | $43.9M | $37.2M | $19.4M | $15.1M | $11.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $3.5M | $3.3M | $3.1M | $625000 | $899000 | $987000 | $831000 | $906000 | $601000 | $601000 |
| Total Assets | $298.7M | $339.8M | $441.8M | $941.2M | $990.0M | $946.0M | $702.6M | $694.0M | $602.6M | $534.7M |
| Accounts Payable | $2.1M | $3.4M | $4.6M | $11.1M | $8.9M | $11.3M | $26.5M | $14.6M | $5.5M | $3.1M |
| Short-term Debt | $7.0M | $7.5M | $12.0M | $1.5M | $26.5M | $5.5M | $7.5M | $3.7M | $4.1M | $4.9M |
| Total Current Liabilities | $204.1M | $273.9M | $265.8M | $139.2M | $180.9M | $226.1M | $96.9M | $51.4M | $41.4M | $46.3M |
| Long-term Debt | 0 | 0 | $357000 | 0 | $14.8M | $14.3M | $10.2M | 0 | 0 | 0 |
| Total Liabilities | $206.3M | $275.8M | $274.8M | $290.8M | $336.5M | $361.9M | $155.1M | $235.7M | $194.7M | $229.0M |
| Retained Earnings | -$160.3M | -$127.9M | -$167.7M | $254.4M | $260.4M | $199.9M | $149.5M | $83.8M | $32.5M | $61.3M |
| Total Equity | $177.7M | $214.3M | $275.5M | $668.0M | $669.7M | $593.5M | $542.2M | $464.1M | $414.7M | $312.1M |
| Total Debt | $7.0M | $7.5M | $12.4M | $39.3M | $76.6M | $52.7M | $46.9M | $25.3M | $22.4M | $19.6M |
| Net Debt | -$275.4M | -$182.2M | -$238.5M | -$123.2M | -$327.3M | -$413.0M | -$303.2M | -$301.8M | -$344.9M | -$259.3M |
| Working Capital | $84.1M | -$75.8M | -$6.0M | $29.6M | $233.4M | $275.7M | $289.3M | $295.8M | $344.9M | $258.7M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 6.59 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 0.25 |
Profitability
| Return on Equity | -31.83% |
| Return on Invested Capital | -19.64% |
| Return on Assets | -20.48% |
| Gross Margin | -471.15% |
| Operating Margin | -2115.41% |
| Net Margin | -2355.50% |
Related companies: CLYM · GNTA · INBX · IVA · KROS · SLN · TARS
Explore sector: Healthcare · Biotechnology
More sections of PRTC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks